Wednesday, May 22 2013 8:20 PM EDT2013-05-23 00:20:52 GMT
The Lee County Sheriff's Department is now working with the Albany Crime stoppers. The Lee County Sheriff's Department asked to join the Albany Crime-stoppers program. The Sheriff's Department believesMore >>
The Lee County Sheriff's Department is now working with the Albany Crime stoppers. The Lee County Sheriff's Department asked to join the Albany Crime-stoppers program. The Sheriff's Department believes it will be a helpful tool in closing some cases.
Wednesday, May 22 2013 8:08 PM EDT2013-05-23 00:08:36 GMT
How would you save your pets life if a tornado touched down here in South Georgia? Tuesday's tornado ripped through Oklahoma taking 24 lives, and today families are still searching for their belongingsMore >>
How would you save your pets life if a tornado touched down here in South Georgia? Tuesday's tornado ripped through Oklahoma taking 24 lives, and today families are still searching for their belongings and pets that were lost during the storm More >>
Wednesday, May 22 2013 6:43 PM EDT2013-05-22 22:43:09 GMT
Some princesses and super heroes made a stop in Albany Wednesday to visit young patients at Phoebe Putney Memorial hospital. Spiderman, Ariel and a few others made rounds to the children on the pediatricMore >>
Some princesses and super heroes made a stop in Albany Wednesday to visit young patients at Phoebe Putney Memorial hospital. More >>
Wednesday, May 22 2013 6:40 PM EDT2013-05-22 22:40:51 GMT
Students and teachers at a south Georgia school dedicated a special spot to a little girl killed in a school bus crash two weeks ago. Several other Pataula Charter Academy students were injured in thatMore >>
Students and teachers at Pataula Charter Academy dedicated a park bench on the playground of the school where 10-year-old Jordyn Doughtie was a student.More >>
Wednesday, May 22 2013 6:31 PM EDT2013-05-22 22:31:56 GMT
Jurors heard closing arguments Wednesday afternoon in the aggravated assault trial of three South Georgia men charged with beating a man in the parking lot of a northwest Albany club. Prosecutors sayMore >>
Prosecutors say three men beat a man in an Albany club parking lot so fiercely they fractured his skull.More >>
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Nektar Therapeutics
SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve, is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.
The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.
Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.
Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.